Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Euroz Hartley's Rottnest Conference 2025
23 slides from Argenica Therapeutics's conference presentation, Mar 13, 2025
Slide 1: Argenica Therapeutics Investor Presentation
ARGENICA THERAPEUTICS INVESTOR PRESENTATION ASX: AGN MANAGING DIRECTOR PRESENTATION EUROZ HARTLEY’S ROTTNEST CONFERENCE 13 MARCH 2025 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Neuroprotection: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Breakthrough Neuroprotective Therapy
BREAKTHROUGH NEUROPROTECTIVE THERAPY ABOUT ARG-007 MISSION Commercialise neuroprotective treatments that minimises brain damage and fosters recovery Cationic poly-arginine peptide following stroke & other neurological conditions ARGENICA THERAPEUTICS Multiple mechanisms of action working across mult
Slide 5: Our Lead Drug Candidate ARG-007
OUR LEAD DRUG CANDIDATE ARG-007 DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Efficacy Safety / Tox STROKE Damage to the brain from interruption of its blood supply SEVERE TBI ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of consciousness HIE Hypoxic ischemic encephalopathy (HIE) d
Slide 6: Potential of ARG-007
POTENTIAL OF ARG-007 MAIN INDICATIONS ADDRESSABLE MARKET SUMMARY OF RESULTS TO DATE STROKE USD$12bn 66% reduction 70% reduction by 20301 in Brain Tissue Death 24 hours after stroke in Brain Tissue Death 28 Days after stroke 1. Coherent Market Insights Report – Acute Ischemic Stroke (AIS) Market Anal
Slide 7: Key Company Metrics
KEY COMPANY METRICS $15.1M $93M +$4M CASH @ BANK 1 MARKET CAP2 NON-DILUTIVE GRANTS 3 ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 95% SHARES ON ISSUE PATIENTS ENROLLED IN PHASE 2 1. Cash balance as @ 31 December 2024 2. Calculated with closing price on @11th March 2025 being $0.73 7 3. Var
Slide 8: Ischaemic Stroke Trial Update
ARGENICA THERAPEUTICS ISCHAEMIC STROKE TRIAL UPDATE 8 www.argenica.com.au
Slide 9: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS 45 SECONDS ONLY 10% 1.9 MILLION How often someone will recover almost brain cells are attacked each suffers an ischaemic completely, due to the extent minute during a stroke3 stroke in
Slide 10: The Stroke Opportunity
The Stroke Opportunity Category Australia United States Number of strokes per year ~45,000 annually1 ~795,000 annually2 Cost of stroke to healthcare USD$71.55 billion in 2012 AUD$5.5 billion expected to increase to system per year in healthcare costs in 20231 USD$184.13 billion by 20303 ARGENICA THE
Slide 11: Encouraging Stroke Results to Date
ENCOURAGING STROKE RESULTS TO DATE SUCCESSFUL PHASE 28 Days 1 (HUMAN after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE FIE
Slide 12: Phase 2 Trial Design in Acute Ischaemic Stroke
PHASE 2 TRIAL DESIGN IN ACUTE ISCHAEMIC STROKE PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of Endpoints patients to meet inclusion 0.3mg/kg ARG-007 or Mortality rate and frequen
Slide 13: Example of What Phase 2 Trial Hopes to Achieve
EXAMPLE OF WHAT PHASE 2 TRIAL HOPES TO ACHIEVE: PROTECTING VULNERABLE BRAIN TISSUE (PENUMBRA) FOLLOWING STROKE & THROMBECTOMY Infarct core: permanent brain cell death Penumbra: Surrounding tissue ARGENICA THERAPEUTICS that is still alive but vulnerable ARG-007 aims to protect the vulnerable penumbra
Slide 14: Phase 2 Clinical Trial in Stroke
PHASE 2 CLINICAL TRIAL IN STROKE 10 Australian hospitals activated to recruit 92 ACTUAL PATIENT RECRUITMENT patients, currently 95% patients dosed. Double-blinded, randomised, placebo- 100 controlled study with 0.3mg/kg dose of ARG- 90 007. ARGENICA THERAPEUTICS 80 70 ARG-007 given to patients that
Slide 15: Investigational New Drug & Fast Track Applications
INVESTIGATIONAL NEW DRUG & FAST TRACK APPLICATIONS The IND application for ARG-007 in AIS is now complete. Regulatory advice has indicated there are advantages to including a Fast Track Application with the IND application. Fast Track is a process designed to facilitate the development and expedite
Slide 16: The Opportunity for ARG-007 in Other Indications
THE OPPORTUNITY ARGENICA THERAPEUTICS FOR ARG-007 IN OTHER INDICATIONS 16 www.argenica.com.au
Slide 17: ARG-007 Potential in TBI – Rat Data
ARG-007 POTENTIAL IN TBI – RAT DATA ARG-007 SIGNIFICANTLY REDUCES NFH PROTEIN AND APP FOLLOWING TBI2 TRAUMATIC 2000 180 BRAIN 1800 160 51% INJURY 1600 52% reduction reduction 140 1400 ARGENICA THERAPEUTICS 120 Density of NFH (mm2) Density of APP (mm2) 1200 100 1000 Estimated USD$18.6bn 80 market siz
Slide 18: Confirmed in Larger Rat Study
CONFIRMED IN LARGER RAT STUDY ARG-007 SIGNIFICANTLY REDUCES KEY TBI BIOMARKERS1 ARGENICA THERAPEUTICS ARG-007 was found to protect brain cells in the injured brain by significantly reducing the accumulation of proteins that contribute to brain cell injury and death following TBI, specifically neurof
Slide 19: ARG-007 Potential in TBI – Ferret Data
ARG-007 POTENTIAL IN TBI – FERRET DATA ARG-007 SIGNIFICANTLY REDUCES AMYLOID PRECURSOR PROTEIN (APP) AND NEUROFILAMENT M-14.9 (RMO-14) & FOLLOWING TBI1 70% 51% 75% 64% reduction reduction ARGENICA THERAPEUTICS ARG-007 was found to protect brain cells in the injured brain by significantly reducing th
Slide 20: ARG-007 Potential in HIE
ARG-007 POTENTIAL IN HIE TOTAL BRAIN INJURY AT 4 WEEK POST HIE WITH ARG-007 TREATMENT OR ARG-007 WITH STANDARD OF CARE HYPOTHERMIA3 HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE) ARGENICA THERAPEUTICS HIE occurs in 1.5 to 2.5 births per 10001 Current standard of care is hypothermia Awarded A$2.5m grant to a
Slide 21: Near-Term Catalysts
NEAR-TERM CATALYSTS Q1/2 CY25 • Investigational New Drug Application and Fast Track ARGENICA THERAPEUTICS Application to be submitted to the FDA • Phase 2 Dosing completed • TBI Preclinical Data • Open IND Q3 CY25 • Release of Phase 2 topline data Q4 CY25 • HIE preclinical data 21 www.argenica.com.a
Slide 22: Near-Term Catalysts and Investment Highlights
3# NEAR-TERM CATALYSTS Several clinical and preclinical data points will be generated over the next 12 months, providing INVESTMENT significant upside to investors. HIGHLIGHTS ARGENICA THERAPEUTICS 1# SOLVING LARGE UNMET NEEDS 2# Nervous system disorders are the SIGNIFICANT PRE- 4# biggest cause of
Slide 23: Argenica Therapeutics Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 23 www.argenica.com.au
Argenica Therapeutics — Euroz Hartley's Rottnest Conference 2025 on 6ix